Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2− Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study

Table 3

Hazard ratios (HRs) comparing everolimus-based therapy and chemotherapy by line of therapy.

Everolimus-based therapy versus chemotherapy^1	Time to discontinuation			Overall survival			Progression-free survival
	HR	95% CI	value	HR	95% CI	value	HR	95% CI	value
Unadjusted
First line	0.32	(0.21, 0.49)		0.47	(0.22, 0.99)		0.87	(0.55, 1.39)	0.561
Second line	0.29	(0.17, 0.50)		0.53	(0.21, 1.29)	0.162	0.59	(0.32, 1.09)	0.093
Third line and above	0.51	(0.31, 0.85)		0.46	(0.20, 1.06)	0.070	0.71	(0.41, 1.24)	0.231
Multivariate-adjusted^2
First line	0.30	(0.20, 0.46)		0.35	(0.16, 0.79)		0.86	(0.53, 1.40)	0.553
Second line	0.30	(0.17, 0.52)		0.53	(0.20, 1.39)	0.195	0.61	(0.32, 1.17)	0.138
Third line and above	0.45	(0.26, 0.78)		0.29	(0.12, 0.75)		0.56	(0.30, 1.02)	0.059

.
Notes:
Chemotherapy was the reference group.
The model adjusted for the following variables: age, line of therapy, adjusted CCI, sites of metastatic disease, ECOG performance status, and prior chemotherapy in the mBC setting at the index therapy initiation date. Insurance plan type, race, disease status, and months from initiation of last adjuvant endocrine therapy to the first stage IV mBC diagnosis were assessed at mBC diagnosis.